A phosphokinome‐based screen uncovers new drug synergies for cancer driven by liver‐specific gain of nononcogenic receptor tyrosine kinases

Yannan Fan, Maria Arechederra, Sylvie Richelme, Fabrice Daian, Chiara Novello, Julien Calderaro, Luca Di Tommaso, Guillaume Morcrette, Sandra Rebouissou, Matteo Donadon, Emanuela Morenghi, Jessica Zucman‐Rossi, Massimo Roncalli, Rosanna Dono, Flavio Maina – 6 June 2017 – Genetic mutations leading to oncogenic variants of receptor tyrosine kinases (RTKs) are frequent events during tumorigenesis; however, the cellular vulnerability to nononcogenic RTK fluctuations has not been characterized.

Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease

Zobair M. Younossi, Maria Stepanova, Nila Rafiq, Linda Henry, Rohit Loomba, Hala Makhlouf, Zachary Goodman – 6 June 2017 – Nonalcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD). The minimal pathologic criteria for NASH include hepatic steatosis, ballooning degeneration, and lobular inflammation. The resolution of NASH, which relies on the loss of ballooning degeneration, is subject to sampling and observer variability in pathologic interpretation.

Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial

Jasmohan S. Bajaj, Zain Kassam, Andrew Fagan, Edith A. Gavis, Eric Liu, I. Jane Cox, Raffi Kheradman, Douglas Heuman, Jessica Wang, Thomas Gurry, Roger Williams, Masoumeh Sikaroodi, Michael Fuchs, Eric Alm, Binu John, Leroy R. Thacker, Antonio Riva, Mark Smith, Simon D. Taylor‐Robinson, Patrick M Gillevet – 6 June 2017 – Recurrent hepatic encephalopathy (HE) is a leading cause of readmission despite standard of care (SOC) associated with microbial dysbiosis. Fecal microbiota transplantation (FMT) may improve dysbiosis; however, it has not been studied in HE.

LiverLearning®: Clinical Hepatology Update 2017

The 2017 Clinical Hepatology Course is a prime opportunity for hepatology professionals to stay updated on the state-of-the-art management of liver disease. Presentations will offer clinically relevant insights on many aspects in patient care in liver disease, and a chance to discuss controversies commonly seen in clinical practice with key leaders in the field. This 1 1/2 day course will offer didactic lectures in 6 topic areas relevant to mid-level hepatology professionals.

aPKC‐ι/P‐Sp1/Snail signaling induces epithelial–mesenchymal transition and immunosuppression in cholangiocarcinoma

Yawei Qian, Wei Yao, Tao Yang, Yan Yang, Yan Liu, Qi Shen, Jian Zhang, Weipeng Qi, Jianming Wang – 2 June 2017 – Cholangiocarcinoma (CCA) is a highly malignant bile duct cancer that tends to invade and metastasize early. The epithelial–mesenchymal transition (EMT) has been implicated in cancer cell invasion and metastasis, as well as in cancer cell evasion of host immunity. In this study, we investigated the interaction between atypical protein kinase C‐iota (aPKC‐ι) and Snail in the regulation of EMT and its relationship to CCA immunosuppression.

Subscribe to